● AI Equity Research · Healthcare

Nuvation Bio Inc. (NUVB)

AI stock analysis · Biotechnology · Last analyzed Jul 8, 2026

Compass Score

3.0/5

Call

Hold

Price

$5.75

AI Target

$12.22 +112.6%

AI Analyst Summary

Nuvation Bio is a clinical-stage biotech with outsized analyst conviction — 9 of 10 covering analysts rate it a Buy — anchored in the potential of its oncology pipeline, most notably its differentiated NUV-868 BET inhibitor program and belrestotug combination therapy. The ~2,599% YoY revenue surge suggests meaningful pipeline progress or partnership milestones that could drive near-term catalysts. The key risk is binary clinical trial outcomes: failure in any pivotal program could rapidly erode the $12.22 consensus price target and the stock's premium valuation.

Catalysts

Phase 2 readout for belrestotug (anti-PD-1/BET inhibitor combo) in solid tumors — efficacy data could serve as a major re-rating event in the near term.
Potential partnership or licensing deal driven by the pipeline's differentiated mechanism of action, monetizing the platform and reducing cash burn concerns.
Continued Phase 1/2 dose-escalation data for NUV-868 establishing proof-of-concept, which could expand addressable indications and attract institutional accumulation.

Risks

Binary clinical risk: a Phase 2 failure in belrestotug or NUV-868 could wipe out a significant portion of the ~112% implied upside to the $12.22 price target in a single data readout.
Cash burn and dilution risk: as a pre-profitability biotech, continued R&D spending may necessitate equity raises, pressuring share price — current ~$5.75 price reflects investor concern.
Competitive oncology landscape: large-cap pharma and well-funded biotechs are advancing BET inhibitor and checkpoint combination therapies, risking pipeline obsolescence or pricing pressure upon potential commercialization.

Fundamentals

Pe N/A (loss-making) · 1.0/5

No trailing P/E available — company is currently unprofitable with a deeply negative forward P/E of -95.8x, typical of early-stage clinical-stage biotech burning cash with no near-term earnings path.

Peg N/A · 3.0/5

PEG ratio is unavailable given negative earnings. Scored neutrally per guidelines; revenue growth of ~2,599% YoY reflects early commercial/trial-stage inflection but does not substitute for earnings-based PEG.

Analyst Rating Strong Buy consensus (1.4) · 5.0/5

9 Buy / 1 Hold / 0 Sell across 9 analysts yields a consensus of 1.4 on the inverted scale, mapping to a score of 5. Broad bullish conviction with no bearish dissent.

Earnings Trend N/A (pre-profitability); Revenue +2,598.7% YoY · 3.0/5

Earnings growth is not meaningful for a pre-profitability biotech. The extraordinary revenue surge signals early pipeline or partnership milestones, but losses are ongoing. Scored neutral pending earnings inflection.

Price Target Beat 2 of 4 quarters beat · 2.0/5

Only 2 of the last 4 quarters showed EPS beats, indicating inconsistent execution against consensus estimates. Limited history and pre-profitability context constrain this assessment.

Management Mixed execution signals · 3.0/5

Strong analyst confidence (9 Buys) partially offsets a below-average EPS beat rate of 2 of 4 quarters. Capital allocation in clinical-stage biotech is difficult to evaluate without profitability data; scored conservatively at neutral.

● See the full picture

Get today's top-scored picks, ranked for you.

Compass screens thousands of stocks every morning and hands you a short list of high-conviction picks — scored, explained, and re-ranked to your risk profile.

Start free for 3 days →

No credit card. Then $9/month. Cancel anytime.

How Compass scores stocks

Compass pre-filters thousands of U.S. equities by fundamentals, then an AI analyst scores each finalist 1–5 across six measures — spanning valuation, growth, analyst sentiment, and management quality — into one composite score, refreshed every market morning. Browse all covered stocks →

Not financial advice. Compass is an analytical tool, not a registered investment adviser or broker-dealer. Scores and recommendations are generated by AI, may be inaccurate or out of date, and are not investment, financial, legal, or tax advice. Investing involves risk, including loss of principal. Do your own research and consult a licensed financial professional. About Compass.